ArticleCancer cell2023
Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma.
Article in Cancer cell, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 43 citations in OpenAlex.
- Early Tumor Shrinkage and Clinical Outcomes for Esophageal Squamous Cell Carcinoma Patients Treated with Immune Checkpoint Inhibitors: Real-World Observational Study.Annals of surgical oncology · 2026Observational
- Transforming perioperative treatment of gastro-oesophageal adenocarcinoma: triumphs, setbacks and future horizons.Nature reviews. Clinical oncology · 2026Review
- A monocyte-centered framework for predicting immunochemotherapy efficacy in lung squamous cell carcinoma patients.EMBO molecular medicine · 2026Article
- Esophageal cancer: from pathogenesis to precision therapies.Signal transduction and targeted therapy · 2026Review
- METTL5 Enables Immune Evasion of Liver Cancer via Chemokine mRNA Translation Regulation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Establishment and evaluation of novel prognostic biomarkers based on systemic coagulation-inflammation index and related genes in breast cancer.Frontiers in immunology · 2026Article
- Tumor cells-derived CXCL17 is associated with up-regulated neutrophil to monocyte ratio and predicts poor prognosis in oral squamous cell carcinoma.Frontiers in oncology · 2026Article
- The predictive value of prognostic immune and nutritional index in esophageal squamous cell carcinoma receiving neoadjuvant immunochemotherapy: a retrospective propensity score matching study.Frontiers in immunology · 2026Article
- Single-cell insights into tumor microenvironment heterogeneity and plasticity: transforming precision therapy in gastrointestinal cancers.Journal of experimental & clinical cancer research : CR · 2025Review
- Positive and negative roles of myeloid cells in cancer immunotherapy.Journal for immunotherapy of cancer · 2025Review
- Variable efficiency of nonsense-mediated mRNA decay across human tissues, tumors and individuals.Genome biology · 2025Article
- Cancer-associated fibroblasts are associated with neo-adjuvant treatment response in oesophageal adenocarcinoma.British journal of cancer · 2025Article
- Tumour Single-Cell Bioinformatics: From Immune Profiling to Molecular Dynamics.Journal of cellular and molecular medicine · 2025Review
- A Multi-marker model based on serum IL-10 predicts response to conversion immunochemotherapy in gastric cancer patients: a retrospective cohort study.BMC gastroenterology · 2025Article
- Epigenomic preconditioning of peripheral monocytes determines their transcriptional response to the tumor microenvironment.Genome medicine · 2025Article
- Cell states and neighborhoods in distinct clinical stages of primary and metastatic esophageal adenocarcinoma.Cell reports. Medicine · 2025Article
- Blockade of CLEVER-1 restrains immune evasion and enhances anti-PD-1 immunotherapy in gastric cancer.Journal for immunotherapy of cancer · 2025Article
- Multimodal sequencing of neoadjuvant nivolumab treatment in hepatocellular carcinoma reveals cellular and molecular immune landscape for drug response.Molecular cancer · 2025Article
- Review
- Identification of an Amino Acid Metabolism Reprogramming Signature for Predicting Prognosis, Immunotherapy Efficacy, and Drug Candidates in Colon Cancer.Applied biochemistry and biotechnology · 2025Article
Corrections and comments
- Commented on by
Authors and funding
32 authors at 14 institutions in 4 countries.
Funding
Abstract
For inoperable esophageal adenocarcinoma (EAC), identifying patients likely to benefit from recently approved immunochemotherapy (ICI+CTX) treatments remains a key challenge. We address this using a uniquely designed window-of-opportunity trial (LUD2015-005), in which 35 inoperable EAC patients received first-line immune checkpoint inhibitors for four weeks (ICI-4W), followed by ICI+CTX. Comprehensive biomarker profiling, including generation of a 65,000-cell single-cell RNA-sequencing atlas of esophageal cancer, as well as multi-timepoint transcriptomic profiling of EAC during ICI-4W, reveals a novel T cell inflammation signature (INCITE) whose upregulation correlates with ICI-induced tumor shrinkage. Deconvolution of pre-treatment gastro-esophageal cancer transcriptomes using our single-cell atlas identifies high tumor monocyte content (TMC) as an unexpected ICI+CTX-specific predictor of greater overall survival (OS) in LUD2015-005 patients and of ICI response in prevalent gastric cancer subtypes from independent cohorts. Tumor mutational burden is an additional independent and additive predictor of LUD2015-005 OS. TMC can improve patient selection for emerging ICI+CTX therapies in gastro-esophageal cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.